BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Shanghai ChemPartner Co., Ltd. Is Pleased to be Part of Agios' Groundbreaking Cancer Research


12/9/2009 10:26:30 AM

SHANGHAI, Dec. 9 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd. (ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, today announced that ChemPartner scientists are pleased to have been involved in recent groundbreaking cancer research from Agios Pharmaceuticals through the companies' ongoing partnership. This breakthrough discovery by Agios scientists was recently published online on November 22nd by Nature in an article entitled "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2HG)".

"The important discovery by Agios and the publication of the Nature article solidifies Agios' leading role in cancer metabolism," Michael Hui, founder and CEO of ChemPartner commented. "ChemPartner has been providing integrated drug discovery research support in the areas of protein science, HTS, enzymology, cell biology, in vivo pharmacology, and DMPK to Agios' innovative R&D programs in the emerging field of cancer metabolism. We congratulate the great achievement by Agios scientists and are also proud of the contribution we made to this partnership. This also demonstrates the quality of scientific work performed at ChemPartner. We look forward to continuing to help Agios advance its drug discovery programs and pipelines."

"The flexibility and expertise of our partners enabled Agios scientists to make this discovery very quickly," said Michael Su, VP Drug Discovery and Interim CSO at Agios Pharmaceuticals. "This new understanding of IDH1 mutants has opened up a new strategy for treating certain forms of cancer. ChemPartner's scientific capabilities will facilitate the continued progress of our drug discovery programs and shorten the time to bring new cancer therapeutics to patients."

About Shanghai ChemPartner

Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 120 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1,000 scientists including over 90 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies.

Further information is available at http://www.shangpharma.com .

CONTACT: Sammi Wang, Public Affairs Department of Shanghai ChemPartner
Co., Ltd., +86-21-5137-1375, yingwang@shangpharma.com

Web site: http://www.shangpharma.com/



Read at BioSpace.com
Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES